Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating restated by research analysts at Stifel Nicolaus in a note issued to investors on Friday, TipRanks reports. They presently have a $127.00 target price on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 21.76% from the company’s current price.
A number of other brokerages have also issued reports on NBIX. Royal Bank of Canada reiterated a “buy” rating and issued a $125.00 price target on shares of Neurocrine Biosciences in a research note on Monday, January 20th. Credit Suisse Group lowered Neurocrine Biosciences from an “outperform” rating to a “neutral” rating and set a $110.00 price target for the company. in a research note on Friday, December 13th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $153.00 price target (up previously from $116.00) on shares of Neurocrine Biosciences in a research note on Thursday, December 12th. TheStreet upgraded Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $125.00 price target (up previously from $102.00) on shares of Neurocrine Biosciences in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and an average target price of $117.54.
Shares of NBIX stock opened at $104.30 on Friday. Neurocrine Biosciences has a 52-week low of $71.85 and a 52-week high of $119.65. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.99 and a current ratio of 7.08. The firm has a market capitalization of $9.63 billion, a PE ratio of 316.06, a PEG ratio of 1.25 and a beta of 1.53. The stock has a fifty day simple moving average of $105.56 and a two-hundred day simple moving average of $102.45.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, February 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.75 by ($0.40). Neurocrine Biosciences had a return on equity of 8.90% and a net margin of 4.70%. The business had revenue of $244.10 million during the quarter, compared to analysts’ expectations of $231.54 million. During the same quarter in the previous year, the company posted $0.19 EPS. The company’s quarterly revenue was up 85.8% on a year-over-year basis. On average, sell-side analysts forecast that Neurocrine Biosciences will post 3.53 EPS for the current fiscal year.
In other Neurocrine Biosciences news, CFO Matt Abernethy sold 1,645 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $116.33, for a total transaction of $191,362.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dimitri E. Grigoriadis sold 5,000 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $115.98, for a total transaction of $579,900.00. Following the transaction, the insider now directly owns 113,408 shares of the company’s stock, valued at approximately $13,153,059.84. The disclosure for this sale can be found here. Insiders have sold a total of 54,286 shares of company stock valued at $5,747,848 in the last three months. Insiders own 4.30% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Altshuler Shaham Ltd lifted its holdings in shares of Neurocrine Biosciences by 172.9% in the 4th quarter. Altshuler Shaham Ltd now owns 262 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Evolution Wealth Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 871.8% in the 4th quarter. Evolution Wealth Advisors LLC now owns 379 shares of the company’s stock valued at $41,000 after acquiring an additional 340 shares during the last quarter. Huntington National Bank lifted its holdings in shares of Neurocrine Biosciences by 43,300.0% in the 4th quarter. Huntington National Bank now owns 434 shares of the company’s stock valued at $47,000 after acquiring an additional 433 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Neurocrine Biosciences in the 4th quarter valued at about $48,000. Finally, Robeco Institutional Asset Management B.V. bought a new position in shares of Neurocrine Biosciences in the 4th quarter valued at about $52,000. 96.46% of the stock is owned by institutional investors and hedge funds.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Article: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.